The 15 most recent market catalysts affecting $SBFM, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Nov 4, 2026
Corporate Catalyst
Neutral
Impact 55
Sunshine Biopharma Inc. Scheduled to Announce Q3 2026 Financial Results
This 8-K filing from Sunshine Biopharma Inc. is a standard pre-earnings announcement, informing the market of the date and time for its Q3 2026 financial results release. The compa…
Oct 8, 2026
Corporate Catalyst
Bearish
Impact 85
Sunshine Biopharma shares are trading lower after the company announced the pricing of its $6 million offering of 10,909,083 units at $0.55 per unnit.
The pricing of Sunshine Biopharma's $6 million offering at $0.55 per unit, below its recent trading price, is a significant negative catalyst for the company. This dilutes the owne…
Oct 8, 2026
Corporate Catalyst
Neutral
Impact 65
Sunshine Biopharma Prices ~$6M Public Offering Of 10,909,083 Units At $0.55/Unit, Each With Two Warrants Exercisable At $0.66
This public offering by Sunshine Biopharma is a corporate catalyst, primarily impacting the company itself. The issuance of new shares and warrants at a price below recent trading …
Sep 28, 2026
Corporate Catalyst
Neutral
Impact 65
Sunshine Biopharma Amends Articles Of Incorporation To Allow For Reverse Stock Split Of Up To 1-For-20; Board Of Directors Has Discretion To Effect The Split
Sunshine Biopharma's CEO, holding 97% of voting power, approved an amendment to allow for a reverse stock split of up to 1-for-20. This action is often a precursor to a company att…
Sep 16, 2026
Corporate Catalyst
Neutral
Impact 65
Sunshine Biopharma Says CEO Steve Slilaty, Holder Of About 97% Of Voting Power, Approved Reverse Stock Split Of Up To 1-For-20 By Written Consent
Sunshine Biopharma's CEO, Steve Slilaty, who controls approximately 97% of the company's voting power, has approved a reverse stock split of up to 1-for-20 by written consent. This…
Sep 16, 2026
Corporate Catalyst
Bullish
Impact 75
EXCLUSIVE: Sunshine Biopharma Advances 'Differentiated Antiviral Candidate' to IND-Enabling Studies
Sunshine Biopharma's announcement that its lead Coronavirus drug candidate is moving into IND-enabling studies is a significant positive development. The preclinical data, includin…
Sep 16, 2026
Corporate Catalyst
Bullish
Impact 75
EXCLUSIVE: Sunshine Biopharma Advances Its Lead Coronavirus Drug Candidate Into IND-Enabling Studies That Showed Broad-Spectrum SARS-CoV-2 Variant Activity In In-Vivo Study
This is a significant positive catalyst for Sunshine Biopharma (SBFM) as it signals advancement of their lead drug candidate into a critical pre-clinical stage before human trials.…
Aug 31, 2026
Corporate Catalyst
Bullish
Impact 55
Sunshine Biopharma Announces Approval Of Atenolol Tablets Of 25mg, 50mg And 100mg For Canadian Market
Sunshine Biopharma has secured Health Canada approval for its generic Atenolol tablets. This is a positive development as it allows SBFM to enter the Canadian market with a well-es…
Aug 19, 2026
Corporate Catalyst
Bullish
Impact 65
Sunshine Biopharma Announces Approval Of Generic Enalapril Tablets 2.5mg, 5mg, 10mg And 20mg For Canadian Market
Sunshine Biopharma has secured approval from Health Canada for its generic Enalapril tablets, a significant step for the company as it expands its product portfolio and market reac…
Aug 19, 2026
Corporate Catalyst
Bullish
Impact 65
EXCLUSIVE: Sunshine Biopharma Secures Canadian Approval for Generic Hypertension Drug
Sunshine Biopharma (SBFM) announced Canadian regulatory approval for its generic hypertension drug, Enalapril, a significant step in expanding its generic drug offerings. This appr…
Aug 19, 2026
Corporate Catalyst
Bullish
Impact 55
EXCLUSIVE: Sunshine Biopharma Receives Canadian Approval for Generic Enalapril for Hypertension in Four Dosage Strengths; Shipping To begin By Year-End 2026
This headline is a corporate catalyst for Sunshine Biopharma, indicating a new product approval and potential revenue stream. The impact is moderate because it's a generic drug, wh…
Aug 4, 2026
Corporate Catalyst
Bullish
Impact 75
Sunshine Biopharma shares are trading higher after the company announced the approval of its generic Dienogest tablets of 2mg for the Canadian market.
This news is a significant positive catalyst for Sunshine Biopharma, as regulatory approval for a generic drug opens up a new revenue stream and market. The approval of Dienogest t…
Aug 4, 2026
Corporate Catalyst
Bullish
Impact 65
EXCLUSIVE: Sunshine Biopharma Targets Canadian Market with New Women's Health Drug Approval
Sunshine Biopharma Inc. (SBFM) has secured regulatory approval in Canada for its generic Dienogest tablets, a significant step into the women's healthcare market for endometriosis …
Aug 4, 2026
Corporate Catalyst
Bullish
Impact 65
EXCLUSIVE: Sunshine Biopharma Gets Canadian Regulatory Approval Of Generic Dienogest Tablets
The Canadian regulatory approval of generic Dienogest tablets is a significant positive catalyst for Sunshine Biopharma (SBFM). This allows them to enter the Canadian market for a …
Jul 20, 2026
Corporate Catalyst
Bullish
Impact 65
Sunshine Biopharma Announces Publication Of New Research Results Demonstrating Efficacy Of A Novel PLpro Inhibitor In Mouse Models Against Three Strains Of SARC-CoV-2 In Vitro
This news is a moderate positive catalyst for Sunshine Biopharma (SBFM) as it validates their research efforts in a critical area. The demonstration of efficacy in mouse models aga…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.